title: Chemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin.
abstract: Regardless of its effect on the concentrations of serum cholesterol, statins exert pleiotropic effects, including the regulation of endothelial function, reduced oxidative stress and inflammation, as well as a slight improvement in the concentrations of high density lipoprotein (HDL). However, its role on the composition of HDL is not yet established. The aim of this study was to evaluate the composition of HDL subfractions, HDLsub>2 and HDL3, after 14 days of placebo and atorvastatin (10 mg/day) use in 30 asymptomatic volunteers. The serum parameters and the HDL subfractions compositions were determined using radiometric, nephelometric and biochemical enzymatic methods. We observed significant reductions of total cholesterol, low density lipoprotein (LDL) and apolipoprotein B-100 by 28%, 40% and 38%, respectively. The analyses of chemical composition of the subfractions revealed a lower lipid protein ratio in HDL2, suggesting enrichment in proteins, and also lower in HDL3, probably by an increase in the number of particles. Several mechanisms can be suggested for the effects observed after the use of atorvastatin, such as a possible action on the reverse cholesterol transport (decreased activity of hepatic lipase and increased phospholipid transfer protein, PLTP), which would explain the enrichment of HDL. The results suggest that statin use may be relevant in the primary prevention of atherosclerosis not only by its lowering effect on LDLcholesterol and its anti-inflammatory effect but also by beneficial changes in HDL subfractions.
authors.forename: Vanessa Helena
authors.initials: VH
authors.lastname: de Souza Zago
authors.forename: José Eduardo
authors.initials: JE
authors.lastname: Tanus-Santos
authors.forename: Mirian Regina
authors.initials: MR
authors.lastname: Gardin Danelon
authors.forename: Eliane Soler
authors.initials: ES
authors.lastname: Parra
authors.forename: Fernanda
authors.initials: F
authors.lastname: Alexandre
authors.forename: Isabela Calanca
authors.initials: IC
authors.lastname: Vieira
authors.forename: Natália Baratella
authors.initials: NB
authors.lastname: Panzoldo
authors.forename: Fábio Luís
authors.initials: FL
authors.lastname: D'Alexandri
authors.forename: Eder Carlos
authors.initials: EC
authors.lastname: Rocha Quintão
authors.forename: Eliana Cotta
authors.initials: EC
authors.lastname: de Faria
mesh_terms: D000328:Adult; D000069059:Atorvastatin; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D053439:Lipoproteins, HDL2 / Q000032:analysis*; D053440:Lipoproteins, HDL3 / Q000032:analysis*; D008297:Male; D011758:Pyrroles / Q000494:pharmacology*
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3; D011758:Pyrroles; D000069059:Atorvastatin